Peptide LexiconAll compounds

Desmopressin: The Nine-Amino-Acid Peptide That Works Even Swallowed — at 0.16% Absorption

Desmopressin (DDAVP) is a synthetic copy of the hormone vasopressin with two changes that make it last longer and act mostly on the kidney. It is one of the few peptide drugs sold as a tablet, even though only about 0.16% of a swallowed dose reaches the blood compared with an injection. Every US nasal-spray brand is now discontinued; a new oral solution was approved in 2026.

FDA-approved (since 1978)Peptide drug taken by mouthBoxed warning: low blood sodium (injection)

Caroline S · Published 2026-09-23

Length

9 amino acids — the same length as the natural hormone vasopressin

Sequence

Vasopressin with two changes: the amino group removed from the first residue (1-desamino) and L-arginine at position 8 replaced by its mirror-image D-arginine (8-D-arginine)

Origin

A synthetic analogue of arginine vasopressin, the body's antidiuretic hormone. The first US approval, Ferring's DDAVP nasal solution, is dated 1978-02-21 in Drugs@FDA

Last reviewed

2026-09-23

What is it good for?

It tells the kidneys to hold on to water. That is why it treats central diabetes insipidus, where the body makes too little vasopressin, and bedwetting in children. Given by injection it also raises the blood-clotting factors VIII and von Willebrand factor, so it is used in mild haemophilia A and type 1 von Willebrand disease. Its main danger is the same action overshooting: too much water held, too little sodium in the blood.

Illustration: A small, clear glass tablet bottle with a copper cap on a white surface, soft shadows.
Illustration

What it is

Desmopressin is a nine-amino-acid peptide drug — a synthetic copy of vasopressin, the hormone the pituitary gland releases to tell the kidneys to keep water. Its label chemical name, 1-desamino-8-D-arginine vasopressin, is a two-item change list:

  • 1-desamino — the amino group on the first residue is removed;
  • 8-D-arginine — the arginine at position 8 is swapped for its mirror-image form, D-arginine.

The effect, as the DDAVP injection label puts it, was a longer duration of action and a much weaker effect on blood vessels and smooth muscle relative to its effect on the kidney. Natural vasopressin raises blood pressure; desmopressin, at the doses used, mostly just holds water. That single design choice is why it became a kidney drug rather than a blood-pressure drug.

How it works

Desmopressin acts on vasopressin V2 receptors in the collecting ducts of the kidney, making them more permeable so more water is pulled back into the body and urine becomes more concentrated. Given by injection, it also releases factor VIII and von Willebrand factor into the blood — the reason it is used in some bleeding disorders.

What it is approved for

Use Form (current US labels)
Central diabetes insipidus Tablet, injection, oral solution
Primary nocturnal enuresis (bedwetting) Tablet
Bleeding in mild haemophilia A and type 1 von Willebrand disease (factor VIII above 5%) Injection

It is not used for nephrogenic diabetes insipidus, where the kidney itself does not respond to the hormone — the labels state that directly.

A peptide that works swallowed — barely

Most peptide drugs are injected because the gut digests them. Desmopressin is one of the few sold as a tablet, and its label is unusually candid about the cost. The DDAVP tablet label puts oral bioavailability at about 5% of the nasal route and about 0.16% of the intravenous route.

0.16% is roughly one molecule in 600. The tablet works anyway because the kidney's V2 receptors respond to vanishingly small amounts; the label's dose-response studies found clinically useful effects from 0.025 mg upward. For anyone trying to understand why most peptides are injected, desmopressin is the clearest worked example of what swallowing one actually costs.

The main risk

The DDAVP injection label opens with a boxed warning for hyponatraemia: holding too much water dilutes the blood's sodium, and severe hyponatraemia "can be life-threatening, leading to seizures, coma, respiratory arrest, or death." The labels contraindicate it in people who already have low sodium, in moderate-to-severe kidney impairment (creatinine clearance below 50 mL/min), and — on the injection label — with loop diuretics and in conditions that cause fluid or electrolyte imbalance, and ask for sodium to be measured within 7 days and about a month after starting.

The danger is not a side effect bolted on; it is the drug's main action going too far.

The shape of the US market

Drugs@FDA lists 38 desmopressin applications on 2026-09-23: 10 brand applications and 28 generics. Read by form, they tell a story no single label does:

  • Every nasal brand is discontinued — DDAVP nasal (first approved 1978-02-21), Concentraid (1990), Stimate (1994), Minirin (2002) and Noctiva (2017).
  • The Nocdurna under-the-tongue tablet (2018) is discontinued too.
  • The brand forms still marketed are the DDAVP tablet (1995), the DDAVP injection (1984) and DESMODA, an oral solution for central diabetes insipidus approved on 25 February 2026 — for adults and children.

The route that launched the drug is gone from the brand list; the route with 0.16% absorption is the one that gained a new brand in 2026.

Where it stands

Approved and generic in the United States; PubMed indexes 6,788 records, 315 tagged as randomised controlled trials (2026-09-23) — among the deepest human evidence bases of any peptide in this library.

Oxytocin, the other nine-amino-acid pituitary hormone, differs from vasopressin at only two positions. Peptide vs protein explains the 40-amino-acid line that keeps desmopressin an ordinary drug. For how few peptides have approved uses at all, see what are peptides used for.

What the research shows

Controls urine output in central diabetes insipidus

FDA-approved indication on the DDAVP tablet, DDAVP injection and DESMODA oral solution labels; dose-response studies on the tablet label

Treats primary nocturnal enuresis (bedwetting)

FDA-approved indication on the DDAVP tablet label (label revision 2021)

Reduces bleeding in mild haemophilia A and type 1 von Willebrand disease

FDA-approved indication on the DDAVP injection label, for patients with factor VIII activity above 5%

Is safe to use without monitoring

No. The injection label carries a boxed warning for hyponatraemia (low blood sodium) that can lead to seizures, coma, respiratory arrest or death, and asks for sodium checks within 7 days and about 1 month after starting

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Approved. Drugs@FDA lists 38 desmopressin applications (2026-09-23): 10 brand applications (NDAs) and 28 generics (ANDAs).

Brands still marketed

DDAVP tablets (NDA019955, 1995), DDAVP injection (NDA018938, 1984) and DESMODA oral solution (NDA219873, approved 2026-02-25).

Discontinued

Every nasal brand — DDAVP nasal (1978), Concentraid (1990), Stimate (1994), Minirin (2002), Noctiva (2017) — and the Nocdurna under-the-tongue tablet (2018).

Published record

PubMed indexes 6,788 records for desmopressin, 315 tagged as randomised controlled trials (2026-09-23).

Frequently asked questions

What is desmopressin?

A man-made version of vasopressin, the hormone that tells the kidneys to keep water. It is nine amino acids long, like the natural hormone, with two small changes that make it last longer and act mainly on the kidney rather than on blood vessels. It has been an FDA-approved medicine since 1978.

What is desmopressin used for?

On current US labels: central diabetes insipidus, where the body makes too little vasopressin and passes large amounts of dilute urine; bedwetting in children (the tablet); and, as an injection, bleeding in people with mild haemophilia A or type 1 von Willebrand disease, because it raises the clotting proteins factor VIII and von Willebrand factor.

Is desmopressin a peptide?

Yes — a nine-amino-acid peptide, well under the 40-amino-acid line US law uses to separate peptides from proteins. It is regulated as an ordinary drug application (NDA), not as a biologic.

How can a peptide work as a tablet?

Mostly by being very potent. Most peptides are broken down in the gut, and desmopressin is no exception: its tablet label puts oral bioavailability at about 0.16% of an intravenous dose. It still works because the kidney responds to tiny amounts, so a tablet dose in the tenths of a milligram delivers enough.

What is the main risk?

Hyponatraemia — too little sodium in the blood — from the body holding too much water. The injection label puts it in a boxed warning and names seizures, coma, respiratory arrest and death as possible outcomes of severe cases. The labels exclude people with low sodium or significant kidney impairment and call for sodium checks after starting.

What happened to desmopressin nasal spray?

In Drugs@FDA, every nasal brand application — DDAVP nasal, Concentraid, Stimate, Minirin and Noctiva — is now listed as discontinued, as is the Nocdurna under-the-tongue tablet. At least one generic nasal spray (Bausch's) is listed as discontinued as well. The forms still marketed by brand are the DDAVP tablet and injection and the DESMODA oral solution approved in 2026.

Is desmopressin the same as vasopressin?

No. Vasopressin is the natural hormone and is also given as a drug, mainly in hospital to raise blood pressure. Desmopressin was designed to keep vasopressin's water-retaining action and lose most of its blood-vessel action, which is why the two are used for different things.